<div id="readability-page-1">Shares of Soleno Therapeutics (SLNO) slumped 7% on Friday afternoon after Scorpion Capital revealed a short position on the stock, citing risks associated with the company’s drug approved for Prader-Willi syndrome. The shortseller alleged several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and cong...</div>

Soleno治療

<p>Soleno Therapeutics（SLNO）的股價在 Scorpion Capital 披露其空頭頭寸後下跌了 7%，報告強調了與其用於普拉德 - 威利綜合症的藥物 Vykat XR 相關的風險。該報告引發了對潛在的前糖尿病/糖尿病、肺水腫及其他健康問題的擔憂。儘管如此，散户投資者對該股票的未來仍持樂觀態度</p>

Soleno 治療的股票下跌，因為 Scorpion Capital 披露了空頭頭寸，但散户投資者尚未表現出悲觀情緒